Prodrugs have emerged as a major strategy for addressing clinical challenges by improving
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …

Prodrug approaches represent an excellent solution to certain pharmaceutical issues
commonly encountered in the drug discovery and development process. Along this line, the …

Classic prodrug strategies rely on covalent modification of active drugs to provide systems
with superior pharmacokinetic properties than the parent drug and facilitate administration …

Bioorthogonal decaging reactions for controllable drug activation within complex biological
systems are highly desirable yet extremely challenging. Herein, we find a new class of Pt (II) …

Prodrugs are molecules with little or no pharmacological activity that are converted to the
active parent drug in vivo by enzymatic or chemical reactions or by a combination of the two …

Bioconjugates represent an emerging class of medicines, which offer therapeutic
opportunities overtaking those of the individual components. Many novel bioconjugates …

Prodrugs are chemically modified drug molecules that are inactive before administration.
After administration, they are converted in situ to parent drugs and induce the mechanism of …

Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or
chemical transformation in vivo to release the active parent drug, which can then exert the …

Smart drugs, such as antibody‐drug conjugates, for targeted therapy rely on the ability to
deliver a warhead to the desired location and to achieve activation at the same site. Thus …

Prodrugs are inactive compounds which are metabolized either chemically or enzymatically
in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can …